WallStreetZenWallStreetZen

NASDAQ: DRIO
Dariohealth Corp Stock Forecast, Predictions & Price Target

Analyst price target for DRIO

Based on 1 analyst offering 12 month price targets for Dariohealth Corp.
Min Forecast
$4.00+150%
Avg Forecast
$4.00+150%
Max Forecast
$4.00+150%

Should I buy or sell DRIO stock?

Based on 1 analyst offering ratings for Dariohealth Corp.
Strong Buy
Strong Buy
1 analysts 100%
Buy
0 analysts 0%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their DRIO stock forecasts and price targets.

DRIO stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2024-04-01

1 of 1

Forecast return on equity

Is DRIO forecast to generate an efficient return?
Company
N/A
Industry
N/A
Market
27.79%

Forecast return on assets

Is DRIO forecast to generate an efficient return on assets?
Company
N/A
Industry
N/A

DRIO revenue forecast

What is DRIO's revenue in the next 2 years based on estimates from 1 analyst?
Avg 1 year Forecast
$31.4M+64.83%
Avg 2 year Forecast
$41.0M+115.08%
DRIO's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

DRIO revenue growth forecast

How is DRIO forecast to perform vs Diagnostics & Research companies and vs the US market?
Company
38.44%
Industry
7.01%
Market
10.58%
DRIO's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
DRIO's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

DRIO vs Diagnostic & Research Stocks

TickerPricePrice TargetUp/downsideConsensus
DRIO$1.60$4.00+150.00%Strong Buy
TTOO$5.06$3.00-40.71%Hold
NOTV$2.11$5.25+148.82%Hold
VNRX$0.68$3.50+414.71%Strong Buy
OCX$2.69$4.42+64.20%Buy

Dariohealth Stock Forecast FAQ

Is Dariohealth Stock a good buy in 2024, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NASDAQ: DRIO) stock is to Strong Buy DRIO stock.

Out of 1 analyst, 1 (100%) are recommending DRIO as a Strong Buy, 0 (0%) are recommending DRIO as a Buy, 0 (0%) are recommending DRIO as a Hold, 0 (0%) are recommending DRIO as a Sell, and 0 (0%) are recommending DRIO as a Strong Sell.

If you're new to stock investing, here's how to buy Dariohealth stock.

What is DRIO's revenue growth forecast for 2024-2025?

(NASDAQ: DRIO) Dariohealth's forecast annual revenue growth rate of 38.44% is forecast to beat the US Diagnostics & Research industry's average forecast revenue growth rate of 7.01%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.58%.

Dariohealth's revenue in 2024 is $19,044,000.On average, 1 Wall Street analysts forecast DRIO's revenue for 2024 to be $939,290,818, with the lowest DRIO revenue forecast at $939,290,818, and the highest DRIO revenue forecast at $939,290,818.

In 2025, DRIO is forecast to generate $1,225,656,320 in revenue, with the lowest revenue forecast at $1,225,656,320 and the highest revenue forecast at $1,225,656,320.

What is DRIO's forecast return on assets (ROA) for 2024-2027?

(NASDAQ: DRIO) forecast ROA is N/A, which is lower than the forecast US Diagnostics & Research industry average of N/A.

What is DRIO's Price Target?

According to 1 Wall Street analyst that have issued a 1 year DRIO price target, the average DRIO price target is $4.00, with the highest DRIO stock price forecast at $4.00 and the lowest DRIO stock price forecast at $4.00.

The Wall Street analyst predicted that Dariohealth's share price could reach $4.00 by Apr 1, 2025. The average Dariohealth stock price prediction forecasts a potential upside of 150% from the current DRIO share price of $1.60.

What is DRIO's forecast return on equity (ROE) for 2024-2027?

(NASDAQ: DRIO) forecast ROE is N/A, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.